US · CTXR
Citius Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cranford, NJ 07016
- Website
- citiuspharma.com
Price · as of 2025-09-30
$0.70
Market cap 8.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $468.75 | ||||
| 2015 | $675.00 | ||||
| 2016 | $288.75 | ||||
| 2017 | $124.00 | ||||
| 2018 | $28.75 | ||||
| 2019 | $11.82 | ||||
| 2020 | $29.50 | ||||
| 2021 | $43.25 | ||||
| 2022 | $28.25 | ||||
| 2023 | $21.38 | ||||
| 2024 | $3.52 | ||||
| 2025 | $1.18 |
AI valuation
Our deep-learning model estimates Citius Pharmaceuticals, Inc.'s (CTXR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.70
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CTXR | Citius Pharmaceuticals, I… | $0.70 | 8.27M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| ADTX | Aditxt, Inc. | $0.46 | 9.84K | +128,310,097% | +775,435,055% | — | +4,369,268,359% | 0.00 | 0.02 | 1.28 | 30.55 | -0.01 | 0.02 | -367.95% | -20796.36% | -25708.85% | -276.39% | 7.12% | -89.79% | 0.78 | -3.78 | 0.09 | 35.64 | -0.23 | 3863.00% | -7923.00% | -984.00% | -9785.19% | -0.72 | 4.28% | 0.00% | 0.00% | 8689.62% | 29.64 | 49.27 | -6164.42 | -10.97 |
| APLM | Apollomics, Inc. | $20.21 | 22.3M | +737% | +1,097% | — | +18,417% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| ATHA | Athira Pharma, Inc. | $6.75 | 26.62M | — | — | — | — | -0.14 | 0.29 | — | 0.38 | — | 0.29 | 0.00% | — | — | -110.77% | 967.28% | -88.52% | 0.03 | — | 4.18 | 3.90 | 0.49 | -1845.00% | — | -381.00% | -740.33% | -7.40 | 931.82% | 0.00% | 0.00% | 0.00% | 0.37 | 0.38 | — | -13.92 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| DARE | Daré Bioscience, Inc. | $1.70 | 16.19M | +12,485% | -31% | — | +2,345% | -6.18 | -4.17 | 2561.95 | -0.46 | — | -4.17 | -146110.22% | -239692.20% | -41430.90% | 73.30% | 135.85% | -18.69% | -0.22 | — | 0.85 | 0.74 | 0.61 | -8843.00% | -9965.00% | -11221.00% | 19.23% | 0.25 | -27.93% | 0.00% | 0.00% | 21.24% | -0.46 | 2.21 | 1090.66 | -14.24 |
| FBLG | FibroBiologics, Inc. Comm… | $0.33 | 13.77M | — | — | — | — | -1.01 | 3.05 | — | -0.92 | -4.28 | 3.05 | 0.00% | — | — | -419.44% | -1119.26% | -143.08% | 0.39 | -81.61 | 3.61 | 2.78 | 0.14 | 2353.00% | — | 3782.00% | -88.80% | -9.32 | -1119.73% | 0.00% | 0.00% | 0.00% | -0.98 | -0.98 | — | -9.77 |
| ICU | SeaStar Medical Holding C… | $2.76 | 7.7M | — | — | — | — | -0.27 | -3.10 | 50.20 | -0.23 | — | -3.10 | 100.00% | -13216.30% | -18392.59% | 309.35% | 425.16% | -607.76% | -0.26 | -73.12 | 0.55 | 0.28 | 0.05 | -7809.00% | — | 5563.00% | -236.21% | -2.34 | 381.44% | 0.00% | 0.00% | 149.78% | -0.31 | -0.35 | 40.98 | -54.76 |
| LNAI | Lunai Bioworks Inc. | $0.37 | 6.59M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| LPTX | Leap Therapeutics, Inc. | $0.62 | 25.83M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- CEO
- Leonard L. Mazur
- Employees
- 23
- Beta
- 1.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.70) − 1 = — (DCF, example).